Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biogen Will Assert New Tecfidera Patent Amid Hexal Germany Launch

Three Dimethyl Fumarate MAAs Were Approved By The EC In May

Executive Summary

Biogen has conceded that generics to its Tecfidera treatment for relapsing remitting multiple sclerosis may launch “at risk” in the EU, after the US-based player was recently granted further patent protection until 2028.

You may also be interested in...



Neuraxpharm Vows Swift Appeal Over Pulled EU Tecfidera Generics

Neuraxpharm has vowed to rapidly challenge a legal decision that has seen generic rivals to Biogen’s Tecfidera (dimethyl fumarate) multiple sclerosis treatment pulled from the market in Europe.

European Regulator Pulls Marketing Authorizations For Tecfidera Generics

In a blow to several generics firms – albeit one telegraphed by a decision handed down nine months ago – the European Commission has ordered the removal of marketing authorizations for generic versions of Biogen’s MS brand, Tecfidera.

Biogen Sees Interest In Potential Biosimilars Deal

As Biogen provided an update on a potential sale of its biosimilars business – with the firm “engaged with multiple interested parties” – it also revealed Q2 sales and offered insights into off-patent competition to its Tysabri and Tecfidera brands.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152046

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel